Lipocine Inc. · NASDAQ:LPCN
Lipocine — J.P. Morgan Healthcare Conference 2026
8 slides from Lipocine's conference presentation, January 2026
Slide 1: LPCN 2203 Oral NAS for Essential Tremor
LPCN 2203 Oral NAS for Essential Tremor
Slide 2: Essential Tremor (ET)
Essential Tremor (ET) No new drug approved in 50+ years • Tremor highly disabling and stigmatizing • Stress can aggravate tremor in social setting • Major impact on activities of daily living leading to unemployment, anxiety and depression1 • Most common impacts on activities of daily living are pou
Slide 3: ET Patient Journey and Commonly used medications
ET Patient Journey and Commonly used medications • First line treatment of propranolol frequently started at PCP • 2nd and 3rd line treatments (e.g., primidone, benzodiazepine, gabapentin, topiramate) at general neurologist and movement disorder clinics • Patient survey indicates on-going management
Slide 4: Essential Tremor Management – Opportunity
Essential Tremor Management – Opportunity Daytime efficacy and improved tolerability remains an unmet need Prevalence Standard of Care Limitations Unmet Need • ~7 million patients in US1 Unfavorable benefit to risk profile3 Superior benefit to risk profile • Most of patients are intolerant or • Impr
Slide 5: Market Potential and Competitive Development Landscape
Market Potential and Competitive Development Landscape $3B+ blockbuster opportunity as 2nd line with 20% peak adoption Products in Development* Estimated ~7 M prevalence 2.2 % of SAGE-324: Adverse events - somnolence population1 68%, dizziness 38%, balance disorder 15%, diplopia 12%, dysarthria 12%,
Slide 6: 2203: Oral GABA Positive Allosteric Modulator
LPCN 2203: Oral GABA Positive Allosteric Modulator Achieved relevant target levels with good tolerability in Phase 1 studies Typical single dose PK profiles LPCN 2203 TEAEs Dose 1 Clinical Study Experience, N=28, 304 doses: Mean Plasma Concentration • LOC 0% Dose 2 • Somnolence, sedation 0% Dose 3 •
Slide 7: LPCN Product Target Differentiation
LPCN Product Target Differentiation Favorable benefit to Novel MOA risk profile Daytime efficacy Endogenous NAS Potential to address anxiety and depression comorbidities Corporate Presentation September 2022 Lipocine | 2024 7
Slide 8: Business Development Contacts
Business Development Contacts Kongnara Papangkorn, Ph.D. Business Development Manager kp@lipocine.com